Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.35 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.33 |
| ▸ | PPARG | P37231 | 7/20 | 0.33 |
| ▸ | PPARD | Q03181 | 7/20 | 0.33 |
| ▸ | PPARA | Q07869 | 7/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.33 |
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2590837 | 0.79 | FFAR3 (0.36) | ALDH1A1MEN1KMT2ACYP1A2THRB | |
| SCHEMBL25547365 | 0.76 | FFAR3 (0.40) | ALDH1A1MEN1KMT2ACYP1A2THRB | |
| SCHEMBL31718805 | 0.75 | EPHX1 (0.47) | ALDH1A1MEN1KMT2AGPR84PPARG | |
| SCHEMBL28436622 | 0.75 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ACYP1A2THRB | |
| SCHEMBL28436624 | 0.75 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ACYP1A2THRB | |
| SCHEMBL28213015 | 0.75 | GPR84 (0.46) | ALDH1A1MEN1KMT2APLA2G2AAKR1B1 | |
| SCHEMBL12227728 | 0.72 | FFAR3 (0.37) | ALDH1A1MEN1KMT2ACYP1A2THRB | |
| SCHEMBL7566798 | 0.72 | LMNA (0.40) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL1983625 | 0.72 | LMNA (0.40) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL11284962 | 0.71 | ADRA1A (0.38) | ALDH1A1MEN1KMT2ACYP1A2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 385 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260002155-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | ALNYLAM PHARMACEUTICALS INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250376682-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | ALNYLAM PHARMACEUTICALS INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250171785-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | BANK OF AMERICA, N.A. | 2025-05-29 | — | — | US | disclosed |
| US-12227744-B2 | Compositions and methods for inhibiting expression of transthyretin | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20240401060-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240327834-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-10-03 | — | — | US | disclosed |
| US-12031133-B2 | GNAQ targeted dsRNA compositions and methods for inhibiting expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240093199-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | ALNYLAM EUROPE AG (DE) | 2024-03-21 | — | — | US | disclosed |
| US-11884919-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230340473-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | ALNYLAM PHARMACEUTICALS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20060094678-A1 | Nuclease resistant double-stranded ribonucleic acid | BANK OF AMERICA, N.A. | 2006-05-04 | — | — | US | disclosed |
| US-20060084621-A1 | Compositions and methods for inhibiting expression of anti-apoptotic genes | ALNYLAM PHARMACEUTICALS, INC. | 2006-04-20 | — | — | US | disclosed |
| WO-2006036916-A2 | RNAI MODULATION OF APOB AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| WO-2006032041-A2 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF ANTI-APOPTOTIC GENES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058266-A1 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | BANK OF AMERICA, N.A. | 2006-03-16 | — | — | US | disclosed |
| WO-2006020768-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| EP-1620544-A2 | MODIFIED iRNA AGENTS | Alnylam Pharmaceuticals Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005115481-A2 | NUCLEASE RESISTANT DOUBLE-STRANDED RIBONUCLEIC ACID | ALNYLAM PHARMACEUTICALS, INC. (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | ALNYLAM PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| WO-2004094595-A2 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058266-A1 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | NSUN2, RNMT, RNGTT | ALDH1A1 4014/4885MEN1 1204/4885KMT2A 380/4885 |
| US-11884919-B2 | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene | SAAL1, APOB, SCARB1 | ALDH1A1 3314/4885MEN1 3540/4885KMT2A 2410/4885 |
| US-20240327834-A1 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SERUM AMYLOID A GENE | SAAL1, APOB, SCARB1 | ALDH1A1 3314/4885MEN1 3540/4885KMT2A 2410/4885 |
| US-20060084621-A1 | Compositions and methods for inhibiting expression of anti-apoptotic genes | BAX, BCL2, API5 | ALDH1A1 3923/4885MEN1 4667/4885KMT2A 3879/4885 |
| US-12031133-B2 | GNAQ targeted dsRNA compositions and methods for inhibiting expression | GNAQ, GNAI1, GNAI2 | ALDH1A1 4541/4885MEN1 2150/4885KMT2A 1133/4885 |
| US-20060094678-A1 | Nuclease resistant double-stranded ribonucleic acid | RNASE1, RNASEH1, RNASEL | ALDH1A1 4166/4885MEN1 1950/4885KMT2A 1821/4885 |
| US-20240401060-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE | EGFR, ERBB3, ERBB2 | ALDH1A1 4646/4885MEN1 4374/4885KMT2A 2158/4885 |
| US-20250376682-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | TTR, RNGTT, RNASE1 | ALDH1A1 3744/4885MEN1 3148/4885KMT2A 3210/4885 |
| US-20240093199-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | PCSK9, PCSK7, RNASE1 | ALDH1A1 4759/4885MEN1 2503/4885KMT2A 1259/4885 |
| US-12227744-B2 | Compositions and methods for inhibiting expression of transthyretin | TTR, RNGTT, RNASE1 | ALDH1A1 3744/4885MEN1 3148/4885KMT2A 3210/4885 |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | LDLR, SLC29A1, SLC29A2 | ALDH1A1 1587/4885MEN1 1466/4885KMT2A 3071/4885 |
| US-20230340473-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | TTR, CRYAA, SARNP | ALDH1A1 1999/4885MEN1 4015/4885KMT2A 3632/4885 |
| US-20250171785-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE PCSK9 GENE | PCSK9, PCSK7, RNASE1 | ALDH1A1 4759/4885MEN1 2503/4885KMT2A 1259/4885 |
| US-20260002155-A1 | SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS | TTR, APOB, APOL1 | ALDH1A1 2381/4885MEN1 3151/4885KMT2A 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.